Epenetos A A, Hooker G, Krausz T, Snook D, Bodmer W F, Taylor-Papadimitriou J
Obstet Gynecol. 1986 Sep;68(3 Suppl):71S-74S.
Immunocytology of ascitic fluid of a patient with ovarian cancer demonstrated reactivity with two tumor-associated monoclonal antibodies, AUA1 and HMFG2. AUA1 radiolabeled with 48.6 mCi 131I was given intraperitoneally. There was a reduction in the rate of reaccumulation of ascites. Cytology of recurrent ascites revealed reactivity with antibody HMFG2 but not AUA1. The patient was further treated intraperitoneally with 39.0 mCi 131I-labeled HMFG2. There has been no reaccumulation of ascites. It is concluded that antibody-guided irradiation may be an effective treatment of malignant ascites secondary to ovarian cancer. Furthermore, this case illustrates the specificity of antibody interactions in the mediation of therapeutic effect and the possibility of tumor selection after irradiation with a single monoclonal antibody. If specificity plays a role, all major specificities should be covered by an appropriate panel of radioactively labeled antibodies. It is recommended that for comprehensive therapy of malignant ascites secondary to ovarian cancer, a mixture of antibodies such as HMFG2 and AUA1 should be used.
一名卵巢癌患者腹水的免疫细胞学检查显示，其与两种肿瘤相关单克隆抗体AUA1和HMFG2发生反应。用48.6毫居里131I标记的AUA1经腹腔注射。腹水再积聚率降低。复发性腹水的细胞学检查显示与抗体HMFG2发生反应，但与AUA1无反应。该患者进一步经腹腔注射39.0毫居里131I标记的HMFG2。此后腹水未再积聚。得出的结论是，抗体导向照射可能是治疗卵巢癌继发恶性腹水的有效方法。此外，该病例说明了抗体相互作用在介导治疗效果中的特异性以及用单一单克隆抗体照射后肿瘤选择的可能性。如果特异性起作用，所有主要特异性应由一组适当的放射性标记抗体覆盖。建议对于卵巢癌继发恶性腹水的综合治疗，应使用HMFG2和AUA1等抗体混合物。
